8-K: Helix Acquisition Corp. II Announces Business Combination Agreement with TheRas, Inc.

Helix Acquisition Corp. II will merge with TheRas, Inc., a clinical-stage biopharmaceutical company, to advance novel small molecule therapeutics targeting RAS and PI3K a malignancies.

Summary

• Helix Acquisition Corp. II (Helix) has entered into a Business Combination Agreement with TheRas, Inc. (BBOT), a clinical-stage biopharmaceutical company.
• The agreement outlines a merger where Helix will de-register in the Cayman Islands and become a Delaware corporation, subsequently merging with BBOT, which will become a wholly-owned subsidiary of Helix.
• Upon domestication, Helix is expected to change its name to BridgeBio Oncology Therapeutics, Inc.
• BBOT stockholders will receive PubCo Common Stock based on a Consideration Ratio, calculated by dividing the Equity Value ($461,051,546) by the Redemption Price.
• The deal includes customary representations, warranties, and covenants for transactions of this type.
• Helix and BBOT will jointly prepare and file a registration statement on Form S-4, including a proxy statement for Helix shareholders to approve the Domestication and Business Combination.
• Closing is subject to customary conditions, including regulatory approvals, shareholder approvals, Nasdaq listing approval, and a minimum cash condition of $400,000,000.
• The Business Combination Agreement may be terminated under customary circumstances, including failure to close by October 31, 2025 (extendable to December 31, 2025), regulatory prohibition, or failure to obtain shareholder approvals.
• BBOT's executive management team is expected to lead PubCo after closing.
• The Sponsor will forfeit Class B Shares immediately prior to the Domestication, with the number of shares forfeited dependent on the Redemption Price.
• Certain Helix shareholders and insiders have entered into a support agreement to vote in favor of the Business Combination.
• BBOT obtained written consents from stockholders holding a sufficient number of shares to approve the Business Combination.
• Helix entered into subscription agreements with PIPE Investors to purchase approximately $260,000,000 of PubCo Common Stock.
• Helix entered into non-redemption agreements with certain shareholders, covering 450,900 Class A Shares.
• The Sponsor, Cormorant, and the Helix Existing Investors will enter into a lock-up agreement, restricting transfer of PubCo Common Stock for one year after the later of the filing of Form 10 Information with the SEC and the Closing Date.
• PubCo, Sponsor, Cormorant, the Helix Existing Investors, and certain former stockholders of BBOT will enter into an amended and restated registration rights agreement.
• PubCo will approve a 2025 Stock Option and Incentive Plan and a 2025 Employee Stock Purchase Plan.
• Helix expects to file the Registration Statement as promptly as practicable and the Closing is expected to occur following the fulfillment or waiver of the closing conditions.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining a strategic merger with significant financial backing. While risks are mentioned, the overall tone suggests confidence in the transaction's success.

Positives

• The merger provides BBOT with access to public markets and capital to further its clinical-stage biopharmaceutical development.
• PIPE Investments of $260,000,000 provide substantial funding for the combined company.
• The executive management team of BBOT is expected to serve as the executive management team of PubCo following Closing.
• The lock-up agreement provides stability in the share price post-merger.

Negatives

• The Sponsor will forfeit Class B Shares, which could be seen as a negative signal.
• The closing is subject to a minimum cash condition of $400,000,000, which may not be met if redemptions are high.
• The lock-up agreement restricts transfer of PubCo Common Stock for one year after the later of the filing of Form 10 Information with the SEC and the Closing Date.

Risks

• Failure to obtain regulatory approvals or shareholder approvals could prevent the closing.
• A Material Adverse Effect on either company could prevent the closing.
• High redemptions by Helix shareholders could jeopardize the minimum cash condition.
• The PIPE Investment may not be fully subscribed.
• The Registration Statement may not be declared effective by the SEC in a timely manner.

Future Outlook

The combined company will focus on advancing BBOT's pipeline of novel small molecule therapeutics targeting RAS and PI3K a malignancies.

Industry Context

This announcement reflects the ongoing trend of SPACs merging with biotech companies to access public markets and fund drug development programs. The focus on oncology therapeutics aligns with the high demand and investment in this sector.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical sector that have gone public through SPAC mergers include companies such as Tango Therapeutics, which merged with Boxer Capital Corp., and Valo Health, which merged with Khosla Ventures Acquisition Co. II.
• The $461 million equity value is within the range of similar biotech SPAC deals.
• The $260 million PIPE investment is a significant commitment, comparable to other well-funded biotech SPAC transactions.
• The one-year lock-up period is standard for SPAC mergers.

Stakeholder Impact

• Shareholders of Helix will have the opportunity to participate in a company focused on oncology therapeutics.
• BBOT stockholders will gain access to public markets and increased capital.
• Employees of both companies may experience changes in roles and responsibilities.
• Customers and suppliers of BBOT can expect continued operations and potential for growth.

Next Steps

• File the Registration Statement with the SEC.
• Solicit proxies from Helix shareholders.
• Obtain regulatory approvals.
• Fulfill closing conditions.
• Close the merger.

Key Dates

Keywords

business combination, merger, biopharmaceutical, oncology, SPAC, Theras, Helix Acquisition Corp II, BBOT, PIPE Investment, Domestication, Redemption, Registration Rights, Lock-Up Agreement